For US Healthcare Professionals
NT1 is associated with a loss of orexin1,2
Orexin is a neuropeptide that helps regulate the “switch” between sleep and wake states3
A loss of orexin destabilizes the switch between sleep and wake states3,4
- In NT1, orexin is diminished and the sleep-wake cycle is dysregulated, causing abrupt transitions between wake and sleep across a 24-hour period3,4
- A loss of orexin signaling results in dysregulation of downstream activity in the brain, which can contribute to a range of NT1 symptoms4,6
NT1 is a chronic neurological disorder;
symptoms affect patients day and night7
The hallmark symptoms of NT1 are sometimes referred to as the pentad7
Scope and severity of NT1 symptoms can vary among individuals.
NT1 symptoms can impact patients’ quality of life and daily functioning8-10
A majority of patients across multiple surveys reported that symptoms can impact:
*Results of an online survey accessible from August 26, 2013, to November 15, 2013, of 1699 US adults with narcolepsy.8
†Results from an online survey conducted in June 2020 of 254 US adults aged 18-39 years with narcolepsy.9
‡Results from a 15-minute online survey conducted in February 2022 of 110 US adults with self-reported NT1 (n=53), NT2 (n=35), or narcolepsy of indeterminate type (n=22).10
Meet Olivia
Meet Olivia
35 YEARS OLD
Diagnosed with NT1
35 YEARS OLD
Diagnosed with NT1
TREATMENT CONSIDERATIONS
- Olivia is currently on treatment and has tried several treatments to manage her NT1
- She has previously tried a wake-promoting therapy during the day and a sleep-inducing therapy at night
- She is experiencing EDS and cataplexy during the day, along with the broader symptoms of NT1
- She is concerned that her NT1 symptoms could be affecting her job
- Olivia made an appointment with her sleep specialist to discuss her concerns
TREATMENT CONSIDERATIONS
- Olivia is currently on treatment and has tried several treatments to manage her NT1
- She has previously tried a wake-promoting therapy during the day and a sleep-inducing therapy at night
- She is experiencing EDS and cataplexy during the day, along with the broader symptoms of NT1
- She is concerned that her NT1 symptoms could be affecting her job
- Olivia made an appointment with her sleep specialist to discuss her concerns
Actor portrayal. Hypothetical patient profile.
Individual results may vary.
Medication may not be appropriate for all patients.
Recommended for you
GABA=gamma-aminobutyric acid; NT1=narcolepsy type 1; NT2=narcolepsy type 2.
References: 1. Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83-93. doi:10.1038/s41583-018-0097-x 2. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662. doi:10.1056/NEJMra1500587 3. De Luca R, Nardone S, Grace KP, et al. Orexin neurons inhibit sleep to promote arousal. Nat Commun. 2022;13(1):4163. doi:10.1038/s41467-022-31591-y 4. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171-181. doi:10.1038/nrn2092 5. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev. 2012;92(3):1087-1187. doi:10.1152/physrev.00032.2011 6. Toor B, Ray LB, Pozzobon A, Fogel SM. Sleep, orexin and cognition. Front Neurol Neurosci. 2021;45:38-51. doi:10.1159/000514960 7. Morse AM, Kim SY, Harris S, Gow M. Narcolepsy: beyond the classic pentad. CNS Drugs. 2025;39(suppl 1):S9-S22. doi:10.1007/s40263-024-01141-9 8. Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419-425. doi:10.5664/jcsm.6494 9. Davidson RD, Biddle K, Nassan M, Scammell TE, Zhou ES. The impact of narcolepsy on social relationships in young adults. J Clin Sleep Med. 2022;18(12):2751-2761. doi:10.5664/jcsm.10212 10. Ortiz LE, Morse AM, Krahn L, et al. A survey of people living with narcolepsy in the USA: path to diagnosis, quality of life, and treatment landscape from the patient's perspective. CNS Drugs. 2025;39(suppl 1):S23-S36. doi:10.1007/s40263-024-01142-8 11. ORZEYFUL (oveporexton tablets) prescribing information. Takeda Pharmaceuticals.